{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:03:20Z","timestamp":1776909800463,"version":"3.51.2"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00246-016-1433-4","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T21:23:50Z","timestamp":1467667430000},"page":"1297-1301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral Enoximone as an Alternative to Protracted Intravenous Medication in Severe Pediatric Myocardial Failure"],"prefix":"10.1007","volume":"37","author":[{"given":"Anke K.","family":"Furck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si\u00e2n","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Bartsota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Rigby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdenek","family":"Slavik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"key":"1433_CR1","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1097\/00003246-199511000-00018","volume":"23","author":"AC Chang","year":"1995","unstructured":"Chang AC, Atz AM, Wernovsky G et al (1995) Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit Care Med 23:1907\u20131914","journal-title":"Crit Care Med"},{"key":"1433_CR2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/01.CIR.0000051365.81920.28","volume":"107","author":"TM Hoffman","year":"2003","unstructured":"Hoffman TM, Wernovsky G, Atz AM et al (2003) Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation 107:996\u20131002","journal-title":"Circulation"},{"key":"1433_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00246-005-0881-z","volume":"26","author":"B Duggal","year":"2005","unstructured":"Duggal B, Pratap U, Slavik Z et al (2005) Milrinone and low cardiac output following cardiac surgery in infants: is there a direct myocardial effect? Pediatr Cardiol 26:1\u20135","journal-title":"Pediatr Cardiol"},{"key":"1433_CR4","doi-asserted-by":"crossref","first-page":"63C","DOI":"10.1016\/0002-9149(87)90528-5","volume":"60","author":"CS Maskin","year":"1987","unstructured":"Maskin CS, Weber KT, Janicki JS (1987) Long-term oral enoximone therapy in chronic cardiac failure. Am J Cardiol 60:63C\u201367C","journal-title":"Am J Cardiol"},{"issue":"S1","key":"1433_CR5","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/0167-5273(90)90149-Y","volume":"28","author":"O Dubourg","year":"1990","unstructured":"Dubourg O, Delorme G, Hardy A et al (1990) Placebo-controlled trial of oral enoximone in end-stage congestive heart failure refractory to optimal treatment. Int J Cardiol 28(S1):S33\u2013S42","journal-title":"Int J Cardiol"},{"key":"1433_CR6","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/0002-8703(91)90154-A","volume":"121","author":"KA Narahara","year":"1991","unstructured":"Narahara KA (1991) Oral enoximone therapy in chronic heart failure: a placebo-controlled randomized trial. The Western Enoximone Study Group. Am Heart J 121:1471\u20131479","journal-title":"Am Heart J"},{"key":"1433_CR7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0167-5273(91)90044-P","volume":"32","author":"JG Coghlan","year":"1991","unstructured":"Coghlan JG, Norell M, Ilsley CD, Mitchell AG (1991) Oral treatment with enoximone in patients referred for cardiac transplantation. Int J Cardiol 32:57\u201363","journal-title":"Int J Cardiol"},{"key":"1433_CR8","unstructured":"http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1419833484287.pdf"},{"key":"1433_CR9","first-page":"S7","volume":"82","author":"AM Katz","year":"1990","unstructured":"Katz AM (1990) Interplay between inotropic and lusitropic effects of cyclic adenosine monophosphate on the myocardial cell. Circulation 82:S7\u2013S11","journal-title":"Circulation"},{"key":"1433_CR10","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1007\/BF02650361","volume":"84","author":"K Chatterjee","year":"1989","unstructured":"Chatterjee K (1989) Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics. Basic Res Cardiol 84:S213\u2013S224","journal-title":"Basic Res Cardiol"},{"key":"1433_CR11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.82.3.774","volume":"82","author":"BF Uretsky","year":"1990","unstructured":"Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J et al (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation 82:774\u2013780","journal-title":"Circulation"},{"key":"1433_CR12","first-page":"1023","volume":"85","author":"G Delorme","year":"1992","unstructured":"Delorme G, Dubourg O, Jondeau G et al (1992) Double-blind clinical and echocardiographic study of oral enoximone versus placebo in severe cardiac insufficiency. Arch Mal Coeur Vaiss 85:1023\u20131029","journal-title":"Arch Mal Coeur Vaiss"},{"key":"1433_CR13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/eurheartj\/15.suppl_3.242","volume":"15","author":"G Jondeau","year":"1994","unstructured":"Jondeau G, Dubourg O, Delorme G et al (1994) Oral enoximone as a substitute for intravenous catecholamine support in end-stage congestive heart failure. Eur Heart J 15:242\u2013246","journal-title":"Eur Heart J"},{"key":"1433_CR14","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0735-1097(98)00077-1","volume":"31","author":"SF Shakar","year":"1998","unstructured":"Shakar SF, Abraham WT, Gilbert EM (1998) Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 31:1336\u20131340","journal-title":"J Am Coll Cardiol"},{"key":"1433_CR15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ahj.2007.06.044","volume":"154","author":"AM Feldman","year":"2007","unstructured":"Feldman AM, Oren RM, Abraham WT et al (2007) Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial. Am Heart J 154:861\u2013869","journal-title":"Am Heart J"},{"key":"1433_CR16","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/eurheartj\/ehp338","volume":"30","author":"M Metra","year":"2009","unstructured":"Metra M et al (2009) Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 30:3015\u20133026","journal-title":"Eur Heart J"},{"key":"1433_CR17","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.CIR.71.5.963","volume":"71","author":"B Massie","year":"1985","unstructured":"Massie B, Bourassa M, DiBianco R et al (1985) Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicentre controlled trial. Circulation 71:963\u2013971","journal-title":"Circulation"},{"key":"1433_CR18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCHEARTFAILURE.114.001218","volume":"8","author":"SJ Nakano","year":"2015","unstructured":"Nakano SJ, Miyamoto SD, Movsesian M et al (2015) Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. Circ Heart Fail 8:57\u201363","journal-title":"Circ Heart Fail"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-016-1433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00246-016-1433-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-016-1433-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:48:34Z","timestamp":1498312114000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00246-016-1433-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["1433"],"URL":"https:\/\/doi.org\/10.1007\/s00246-016-1433-4","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,5]]}}}